Global Antibodies Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Type;

Monoclonal Antibodies, Polyclonal Antibodies, and Antibody-Drug Complexes (ADCs)

By Disease Indication;

CNS Disorders, Cardiovascular Diseases, Cancer, and Autoimmune Disorders

By End User;

Hospitals, Long-Term Care Facilities, Research Institutes

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn412301019 Published Date: June, 2025 Updated Date: July, 2025

Antibodies Market Overview

Antibodies Market (USD Million)

Antibodies Market was valued at USD 238,520.98 million in the year 2024. The size of this market is expected to increase to USD 467,775.87 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.1%.


Global Antibodies Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 10.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)10.1 %
Market Size (2024)USD 238,520.98 Million
Market Size (2031)USD 467,775.87 Million
Market ConcentrationLow
Report Pages371
238,520.98
2024
467,775.87
2031

Major Players

  • Novartis A F.
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Antibodies Market

Fragmented - Highly competitive market without dominant players


The Antibodies Market is rapidly evolving, driven by the growing integration of monoclonal antibodies into targeted treatment regimens. Over 72% of biologic development pipelines now include antibody-based solutions, underscoring their expanding use in addressing diseases such as cancer and immune disorders. The increasing role of immunotherapy continues to elevate their clinical relevance.

Technology-Driven Development
Advancements in biotechnology, including recombinant platforms and hybridoma engineering, are responsible for nearly 58% of recent antibody innovations. These technologies have led to the creation of advanced formats like bispecific and conjugated antibodies that improve therapeutic performance.

Growing R&D Emphasis
Close to 60% of total biopharmaceutical research funding is now allocated to antibody-related development. This investment supports clinical trials, optimization studies, and next-generation antibody formats, reflecting the industry’s commitment to precision-targeted biologics.

Strong Regulatory Momentum
With 54% of new biologic approvals involving antibodies, regulatory agencies are showing growing support for antibody-based drugs. This favorable landscape is encouraging accelerated submissions and approvals, particularly for therapies addressing high-burden diseases.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Disease indication
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Antibodies Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Biopharmaceutical advancements

        2. Increasing prevalence of chronic diseases

        3. Growing demand for personalized medicine

      2. Restraints
        1. High cost

        2. Limited manufacturing capacity

        3. Intellectual property issues

      3. Opportunities
        1. Emerging markets expansion

        2. Development of novel therapeutics

        3. Advances in diagnostics

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Antibodies Market, By Drug Type, 2021 - 2031 (USD Million)
      1. Monoclonal Antibodies

      2. Polyclonal Antibodies

      3. Antibody-Drug Complexes (ADCs)

    2. Antibodies Market, By Disease indication, 2021 - 2031 (USD Million)
      1. CNS Disorders

      2. Cardiovascular Diseases

      3. Cancer

      4. Autoimmune Disorders

    3. Antibodies Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Long-Term Care Facilities
      3. Research Institutes
    4. Antibodies Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis A F.
      2. Hoffmann-La Roche Ltd.
      3. Johnson & Johnson Services, Inc.
      4. Takeda Pharmaceutical Company Limited
      5. Amgen Inc.
      6. Biogen Inc.
      7. Bristol-Myers Squibb Company
  7. Analyst Views
  8. Future Outlook of the Market